By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia today announced that insurer Humana will provide reimbursement for the firm's MammaPrint breast cancer recurrence test.

The Dutch molecular diagnostics firm said that the contract with Humana will expand coverage for MammaPrint by more than 17 million lives. Coding guidelines for the test were established in November 2009 by Palmetto GBA, California's Part B Medicare administrator.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.